Intra-Cellular Therapies Inc (ITCI) CEO Sharon Mates Sells 6,604 Shares

Intra-Cellular Therapies Inc (NASDAQ:ITCI) CEO Sharon Mates sold 6,604 shares of Intra-Cellular Therapies stock in a transaction on Monday, January 7th. The stock was sold at an average price of $12.43, for a total value of $82,087.72. Following the completion of the transaction, the chief executive officer now owns 1,190,909 shares in the company, valued at $14,802,998.87. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sharon Mates also recently made the following trade(s):

  • On Friday, January 4th, Sharon Mates sold 45,598 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $11.45, for a total value of $522,097.10.
  • On Wednesday, January 2nd, Sharon Mates sold 17,478 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $11.09, for a total value of $193,831.02.

Shares of ITCI stock opened at $13.14 on Friday. Intra-Cellular Therapies Inc has a 1-year low of $10.21 and a 1-year high of $25.82. The firm has a market cap of $718.01 million, a PE ratio of -6.20 and a beta of 1.30.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. As a group, analysts expect that Intra-Cellular Therapies Inc will post -2.95 EPS for the current fiscal year.

A number of equities analysts recently issued reports on the company. Zacks Investment Research cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Thursday. Cantor Fitzgerald set a $32.00 target price on Intra-Cellular Therapies and gave the stock a “buy” rating in a report on Tuesday, October 23rd. Royal Bank of Canada lifted their target price on Intra-Cellular Therapies from $35.00 to $37.00 and gave the stock an “outperform” rating in a report on Wednesday, December 12th. BidaskClub upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Friday, September 28th. Finally, ValuEngine cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Thursday, November 15th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $27.75.

Several hedge funds have recently modified their holdings of the company. Schroder Investment Management Group acquired a new stake in Intra-Cellular Therapies during the second quarter valued at $21,222,000. Franklin Resources Inc. acquired a new stake in Intra-Cellular Therapies during the third quarter valued at $10,700,000. Point72 Asset Management L.P. boosted its position in Intra-Cellular Therapies by 234.2% during the third quarter. Point72 Asset Management L.P. now owns 634,466 shares of the biopharmaceutical company’s stock valued at $13,768,000 after purchasing an additional 444,609 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in Intra-Cellular Therapies by 131.2% during the third quarter. Candriam Luxembourg S.C.A. now owns 548,000 shares of the biopharmaceutical company’s stock valued at $11,892,000 after purchasing an additional 311,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Intra-Cellular Therapies by 13.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,356,720 shares of the biopharmaceutical company’s stock valued at $23,974,000 after purchasing an additional 159,860 shares during the last quarter. Institutional investors and hedge funds own 69.53% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Intra-Cellular Therapies Inc (ITCI) CEO Sharon Mates Sells 6,604 Shares” was first posted by WKRB News and is the property of of WKRB News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2019/01/11/intra-cellular-therapies-inc-itci-ceo-sharon-mates-sells-6604-shares.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Read More: Bollinger Bands

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply